Document:

Exhibit 10.5

 

DIRECTOR AGREEMENT

 

This DIRECTOR AGREEMENT is made as of June 23, 2016 (the “Agreement”), by and between Osiris Therapeutics, Inc., a Maryland corporation (the “Company”), and Thomas M. Brandt, Jr. (the “Director”).

 

WHEREAS, on March 3, 2016, the Company appointed the Director to its Board of Directors, and desires to enter into an agreement with the Director with respect to such appointment; and

 

WHEREAS, the Director is willing to accept such appointment and to serve the Company on the terms set forth herein and in accordance with the provisions of this Agreement.

 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the parties hereto agree as follows:

 

1.                                      Position. Subject to the terms and provisions of this Agreement, the Company shall cause the Director to be appointed a Director of the Company in the class of directors up for election at the 2016 Annual Meeting of Stockholders (the “2016 Annual Meeting”) immediately upon the execution of this Agreement, and the Director hereby agrees to serve the Company in such position, upon the terms and conditions hereinafter set forth, and in accordance with the duties imposed by Maryland law, the Company’s Articles of Restatement, the Company’s By Laws (the “Bylaws”) and applicable stock exchange regulations, provided, however, that the Director’s continued service on the Board of Directors of the Company (the “Board”) for any period following the 2016 Annual Meeting shall be subject to the nomination of the Director for election by the Company’s stockholders by the Company’s Nominating Committee for such period, and the election of the Director by the stockholders of the Company.

 

2.                                      Duties.

 

(a)                                           During the Directorship Term (as defined in Section 4 below), the Director shall make reasonable business efforts to attend all Board meetings, serve on appropriate committees as reasonably requested by the Board, make himself available to the Company at mutually convenient times and places, attend external meetings and presentations, as appropriate and convenient, and perform such duties, services and responsibilities, and have the authority commensurate to such position.

 

(b)                                            The Director will use his reasonable best efforts to promote the interests of the Company and devote such time to the Company’s affairs as required to appropriately discharge his duties and legal obligations as a Director. Other than as set forth above, the Director will not, without the prior notification to the Board, engage in any other business activity which could materially interfere with the performance of his duties, services and responsibilities hereunder or which is in violation of the reasonable policies established from time to time by the Company. At such time as the Board receives such notification, the Board may require the resignation of the Director if it determines that such business activity does in fact materially interfere with the performance of the Director’s duties, services and responsibilities hereunder.

 

3.                                      Compensation.

 

(a)                                             The Company agrees to pay Director a fee of $60,000 per annum, pro-rated if the Directorship Term (as defined in Section 4 below) is less than one year, which will be payable upon the conclusion of the Directorship Term. The Company and the Director acknowledge that under the Bylaws of the Company, the Board of Directors shall have authority to fix the compensation of directors.

 

(b)                                             During the Directorship Term, the Company shall reimburse the Director for all reasonable out-of-pocket expenses incurred by the Director in attending any in-person meetings, provided that the Director complies with the generally applicable policies, practices and procedures of the Company for submission of expense reports, receipts or similar documentation of such expenses. Any reimbursements for allocated expenses (as

 

1

 

compared to out-of-pocket expenses of the Director) must be approved in advance by the Company.

 

(c)                                              The Company will maintain a customary director and officer liability insurance policy for all Board members and such policy will cover Director to the same extent as other directors and officers covered under the policy.

 

(d)                                             The Director’s status during the Directorship Term shall be that of an independent contractor and not, for any purpose, that of an employee or agent with authority to bind the Company in any respect. All payments and other consideration made or provided to the Director under this Section 3 shall be made or provided without withholding or deduction of any kind, and the Director shall assume sole responsibility for discharging all tax or other obligations associated therewith.

 

4.                                      Directorship Term. The “Directorship Term,” as used in this Agreement, shall mean the period commencing on the date hereof and terminating on the earlier of the date of the next annual stockholders meeting and the earliest of the following to occur:

 

(a)                                             the death of the Director;

 

(b)                                             the termination of the Director from his membership on the Board by the mutual written agreement of the Company and the Director;

 

(c)                                              the removal of the Director from the Board in accordance with the Bylaws and Maryland law; and

 

(d)                                             the resignation by the Director from the Board.

 

5.                                      Director’s Representations and Acknowledgment.

 

(a)                                             The Director acknowledges and agrees that his position as member of the Board will result in him being deemed to be an “affiliate” of the Company for purposes of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and the regulations promulgated thereunder (collectively, the “Securities Laws”).

 

(b)                                             The Director represents to the Company that his execution and performance of this Agreement shall not be in violation of any agreement or obligation (whether or not written) that he may have with or to any person or entity, including without limitation, any prior or current employer. The Director hereby acknowledges and agrees that this Agreement (and any other agreement or obligation referred to herein) shall be an obligation solely of the Company, and the Director shall have no recourse whatsoever against any officer, director, employee, stockholder, representative or agent of the Company or any of their respective affiliates with regard to this Agreement.

 

6.                                      Director Covenants.

 

(a)                                             Unauthorized Disclosure. The Director agrees and understands that in the Director’s position with the Company, the Director has been and will be exposed to and receive information relating to the confidential affairs of the Company, including, but not limited to, technical information, business and marketing plans, strategies, customer information, other information concerning the Company’s products, services, promotions, development, financing, expansion plans, business policies and practices, and other forms of information considered by the Company to be confidential, and proprietary and in the nature of trade secrets. The Director agrees that during the Directorship Term and thereafter, subject to his fiduciary duties, the Director will keep such information confidential and will not disclose such information, either directly or indirectly, to any third person or entity without the prior written consent of the Company; provided, however, that (i) the Director shall have no such obligation to the extent such information (A) is or becomes publicly known or generally known in the Company’s industry other than as a result of the Director’s breach of his obligations hereunder, (B) is lawfully obtained from a source other than the Company that was not under, and did not impose, an obligation of confidentiality with respect to such information;

 

2

 

(C) is independently developed by Director or his Affiliates without violating any of his obligations under this Agreement; and (D) is or becomes known by the Director other than through disclosure by the Company in the course of the Directorship Term; and (ii) the Director may, after giving prior notice to the Company to the extent practicable under the circumstances, disclose such information to the extent required by applicable laws or governmental regulations or judicial or regulatory process. This confidentiality covenant has no geographical or territorial restriction. Upon termination of the Directorship Term, the Director will promptly destroy all property, keys, notes, memoranda, writings, lists, files, reports, customer lists, correspondence, tapes, disks, cards, surveys, maps, logs, machines, technical data, other product or document, and any summary or compilation of the foregoing, in whatever form, including, without limitation, in electronic form, which has been produced by, received by or otherwise submitted to the Director in the course or otherwise as a result of the Director’s position with the Company during or prior to the Directorship Term, provided that the Company shall retain such materials and make them available to the Director if requested by him in connection with any litigation against the Director under circumstances in which (i) the Director demonstrates to the reasonable satisfaction of the Company that the materials are necessary to his defense in the litigation and (ii) the confidentiality of the materials is preserved to the reasonable satisfaction of the Company.

 

(b)                                              Company Policies. Director acknowledges that he has received and reviewed a copy of the Company’s Code of Business Conduct and Ethics, and its Supplemental Securities Trading Policy for Officers, Directors and Key Employees (the “Policies”), and understands and agrees that he will strictly comply with all the requirements of the Policies during the Directorship Term and so for so long thereafter as specifically required by the Policies, including without limitation the provisions thereof concerning unauthorized communication of internal Company information to third parties, including responses to inquiries by the financial press, investment analysts, investors, or other members of the financial community.

 

(c)                                              Non-Solicitation. During the Directorship Term and for a period of two (2) years thereafter, the Director shall not interfere with the Company’s relationship with, or endeavor to entice away from the Company, any person who, on the date of the termination of the Directorship Term and/or at any time during the one year period prior to the termination of the Directorship Term, was an employee or customer (including those reasonably expected to be a customer) of the Company or otherwise had a material business relationship with the Company.

 

(d)                                             Remedies. The Director agrees that any breach of the terms of this Section 6 could result in irreparable injury and damage to the Company for which the Company could have no adequate remedy at law. The Director therefore also agrees that in the event of said breach or any threat of breach, the Company shall be entitled to seek an immediate injunction and restraining order to prevent such breach and/or threatened breach and/or continued breach by the Director and/or any and all of his affiliates, without having to prove damages or paying a bond, in addition to any other remedies to which the Company may be entitled at law or in equity. The terms of this paragraph shall not prevent the Company from pursuing any other available remedies for any breach or threatened breach hereof, including, but not limited to, the recovery of damages from the Director. The Director acknowledges that the Company would not have entered into this Agreement had the Director not agreed to the provisions of this Section 7.

 

(e)                                              Survival. The provisions of this Section 6 shall survive any termination of the Directorship Term, and the existence of any claim or cause of action by the Director against the Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement by the Company of the covenants and agreements of this Section 6.

 

7.                                      Non-Waiver of Rights. The failure to enforce at any time the provisions of this Agreement or to require at any time performance by the other party hereto of any of the provisions hereof shall in no way be construed to be a waiver of such provisions or to affect either the validity of this Agreement or any part hereof, or the right of either party hereto to enforce each and every provision in accordance with its terms. No waiver by either party hereto of any breach by the other party hereto of any provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions at that time or at any prior or subsequent time.

 

3

 

8.                                      Notices. Every notice relating to this Agreement shall be in writing and shall be given by personal delivery, overnight delivery or by registered or certified mail, postage prepaid, return receipt requested; to:

 

If to the Company:

 

Chairman of the Board

Osiris Therapeutics, Inc.

7015 Albert Einstein Drive Columbia, MD 21046

 

with a copy (which shall not constitute notice) to:

 

General Counsel

Osiris Therapeutics, Inc.

7015 Albert Einstein Drive Columbia, MD 21046

 

If to the Director:

 

Thomas M. Brandt, Jr. 474 Old Orchard Circle Millersville, MD 21108

 

with a copy (which shall not constitute notice) to:

 

Clifford Geiger

Kollman & Saucier, P.A.

1823 York Road

The Business Law Building Timonium, Maryland 21093

 

Either of the parties hereto may change their address for purposes of notice hereunder by giving notice in writing to such other party pursuant to this Section 10.

 

9.                                      Binding Effect/Assignment. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective heirs, executors, personal representatives, estates, successors (including, without limitation, by way of merger) and assigns, as applicable. Notwithstanding the provisions of the immediately preceding sentence, neither the Director nor the Company shall assign all or any portion of this Agreement without the prior written consent of the other party.

 

10.                               Entire Agreement. This Agreement sets forth the entire understanding of the parties hereto with respect to the subject matter hereof and supersedes all prior agreements, written or oral, between them as to such subject matter.

 

11.                               Severability. If any provision of this Agreement, or any application thereof to any circumstances, is invalid, in whole or in part, such provision or application shall to that extent be severable and shall not affect other provisions or applications of this Agreement.

 

12.                               Governing Law. This Agreement shall be governed by and construed m accordance with the laws of the State of Maryland, without reference to the principles of conflict of laws. Neither party hereto shall commence any action or proceeding arising out of or relating to this Agreement unless prior thereto the parties have in good faith attempted to resolve the claim, dispute or cause of action which is the subject of such action or proceeding through mediation by an independent third party.

 

13.                               Modifications. Neither this Agreement nor any provision hereof may be modified, altered, amended or waived except by an instrument in writing duly signed by the party to be charged.

 

14.                               Tense and Headings. Whenever any words used herein are in the singular form, they shall be construed as though they were also used in the plural form in all cases where they would so apply. The headings

 

4

 

contained herein are solely for the purposes of reference, are not part of this Agreement and shall not in any way affect the meaning or interpretation of this Agreement.

 

15.                               Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.

 

IN WITNESS WHEREOF, the Company has caused this Director Agreement to be executed by authority of its Board of Directors, and the Director has hereunto set his hand, on the day and year first above written.

 

 

	
Osiris Therapeutics, Inc.
    	
 
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
/S/ ADRIAN MOLLO
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
DIRECTOR
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
/S/ Thomas M. Brandt, Jr.
    	
 
    
	
Thomas   M. Brandt, Jr
    	
 
    

 

5Exhibit 10.6

 

 

April 17, 2017

 

By email (yc506@yahoo.com)

 

Linda L. Chang

141 Central Avenue

Gaithersburg, MD 20877

 

Re:                             Chief Financial Officer, Osiris Therapeutics, Inc.

 

Dear Ms. Chang:

 

We are delighted to extend this offer of employment for the position of Chief Financial Officer of Osiris Therapeutics, Inc. (“Osiris” or “the Company”).  Please note that this offer is subject to approval by our Company’s Board of Directors.  If you accept this offer, and once ratified by our Board, your employment will start on May 1, 2017.

 

These are the offered terms and conditions of employment:

 

1.                                      Position.  Your title will be Chief Financial Officer.  You will report directly to the Company’s President and Chief Executive Officer.  This is a full-time position.  While you are employed at this Company, you will not engage in any other employment, consulting, or other business activity (whether full-time or part-time) that would create a conflict of interest with the Company.  By signing this letter of agreement, you confirm that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company.

 

2.                                      Base Compensation.  The Company will pay you an annual salary of $320,000, subject to reduction to reflect applicable withholding of payroll taxes and other deductions required by law.  This salary shall be payable in equal biweekly installments in accordance with the Company’s standard payroll schedule.

 

3.                                      Bonus.  You will be eligible to earn a bonus each year up to $80,000, to be determined by the Compensation Committee of the Board of Directors in accordance with the Company’s Compensation Policy and the Compensation Committee Charter.  In addition, you will be entitled to participate in a long-term incentive plan, such plan to be designed by the Compensation Committee (subject to Board approval) by or before December 31, 2017.  In the event of a change in control of the Company any grants or awards under the long-term incentive plan shall immediately become vested.

 

4.                                      Employee Benefits.  You will be eligible to participate in a number of Company-sponsored employee benefit plans on the same terms and conditions as other executives of the Company.  The Company offers a comprehensive employee benefits programs, including but not limited to: medical insurance, vision plan, dental insurance, flexible spending accounts, life insurance and

 

 

AD&D, short-term disability, long-term disability, and a 401(k) plan with a partial Company match.  In addition, you will be eligible to receive the same perquisites as other officers of the Company.

 

5.                                      Paid Time Off.  You will be entitled to receive paid Company holidays and accrue paid time off (PTO) in the same manner as other executives of the Company, including PTO accruing at an annual rate of 168 hours, plus 8 paid holidays and 2 paid personal (floater) day per calendar year.

 

6.                                      Employment Relationship.  Your employment with the Company will be “at will,” meaning that either you or the Company may terminate your employment at any time and for any reason, with or without cause.  As part of and a condition of this offer, you will be provided with and asked to sign and accept certain Company agreements and policies, in the same manner as other executives of the Company, including a non-disclosure and non-competition agreement (provided separately) and the Company’s Code of Conduct.

 

7.                                      Severance.  In the event of your termination by the Company without cause, you will be paid severance equivalent to six month salary.

 

8.                                      Interpretation, Amendment and Enforcement.  This letter of agreement supersedes and replaces any prior agreements, representations or understandings between you and the Company and constitutes the complete agreement between you and the Company regarding the subject matter set forth herein.

 

You may indicate your agreement with these terms and accept this offer by signing and dating this agreement.

 

 

	
 
    	
Osiris Therapeutics, Inc.
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/S/ D.A. DRESNER
    
	
 
    	
Name: David A. Dresner
    
	
 
    	
Title: Interim Chief   Executive Officer
    
	
 
    	
 
    
	
 
    	
 
    
	
Acknowledgement and   Agreement:
    	
 
    
	
 
    	
 
    
	
/S/ Linda Chang
    	
 
    
	
Linda L. Chang
    	
 
    
	
 
    	
 
    
	
5/17/17
    	
 
    
	
Date
    	
 
    

 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}]]